322 related articles for article (PubMed ID: 29210777)
21. Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058.
van de Vijver DAMC; Richter AK; Boucher CAB; Gunsenheimer-Bartmeyer B; Kollan C; Nichols BE; Spinner CD; Wasem J; Schewe K; Neumann A
Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782266
[TBL] [Abstract][Full Text] [Related]
22. The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil.
Luz PM; Osher B; Grinsztejn B; Maclean RL; Losina E; Stern ME; Struchiner CJ; Parker RA; Freedberg KA; Mesquita F; Walensky RP; Veloso VG; Paltiel AD
J Int AIDS Soc; 2018 Mar; 21(3):e25096. PubMed ID: 29603888
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study.
Nichols BE; Boucher CAB; van der Valk M; Rijnders BJA; van de Vijver DAMC
Lancet Infect Dis; 2016 Dec; 16(12):1423-1429. PubMed ID: 27665989
[TBL] [Abstract][Full Text] [Related]
24. Piloting a partially self-financed mode of human immunodeficiency virus pre-exposure prophylaxis delivery for men who have sex with men in Hong Kong.
Lee SS; Kwan TH; Wong NS; Lee KCK; Chan DPC; Lam TTN; Lui GCY
Hong Kong Med J; 2019 Oct; 25(5):382-391. PubMed ID: 31619578
[TBL] [Abstract][Full Text] [Related]
25. Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel.
Ginsberg GM; Chemtob D
BMC Public Health; 2020 Feb; 20(1):271. PubMed ID: 32103750
[TBL] [Abstract][Full Text] [Related]
26. Comparison between daily and on-demand PrEP (pre-exposure prophylaxis) regimen in covering condomless anal intercourse for men who have sex with men in Hong Kong: A randomized, controlled, open-label, crossover trial.
Kwan TH; Lui GCY; Lam TTN; Lee KCK; Wong NS; Chan DPC; Lee SS
J Int AIDS Soc; 2021 Sep; 24(9):e25795. PubMed ID: 34473402
[TBL] [Abstract][Full Text] [Related]
27. Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study).
King HL; Keller SB; Giancola MA; Rodriguez DA; Chau JJ; Young JA; Little SJ; Smith DM
AIDS Behav; 2014 Sep; 18(9):1722-5. PubMed ID: 25017425
[TBL] [Abstract][Full Text] [Related]
28. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
Mugwanya K; Baeten J; Celum C; Donnell D; Nickolas T; Mugo N; Branch A; Tappero J; Kiarie J; Ronald A; Yin M; Wyatt C;
J Infect Dis; 2016 Oct; 214(7):1050-7. PubMed ID: 27029778
[TBL] [Abstract][Full Text] [Related]
29. Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial.
Delaugerre C; Rodriguez C; Capitant C; Nere ML; Mercier-Darty M; Carette D; Pialoux G; Cotte L; Charreau I; Molina JM;
AIDS; 2018 Oct; 32(16):2353-2361. PubMed ID: 30096070
[TBL] [Abstract][Full Text] [Related]
30. Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment.
Reyes-Urueña J; Campbell C; Diez E; Ortún V; Casabona J
AIDS Care; 2018 Jun; 30(6):784-792. PubMed ID: 29262694
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States.
Brogan AJ; Davis AE; Mellott CE; Fraysse J; Metzner AA; Oglesby AK
Pharmacoeconomics; 2024 Apr; 42(4):447-461. PubMed ID: 38267806
[TBL] [Abstract][Full Text] [Related]
32. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
Solomon MM; Mayer KH; Glidden DV; Liu AY; McMahan VM; Guanira JV; Chariyalertsak S; Fernandez T; Grant RM;
Clin Infect Dis; 2014 Oct; 59(7):1020-6. PubMed ID: 24928295
[TBL] [Abstract][Full Text] [Related]
33. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.
Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ
Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634
[TBL] [Abstract][Full Text] [Related]
34. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
Molina JM; Capitant C; Spire B; Pialoux G; Cotte L; Charreau I; Tremblay C; Le Gall JM; Cua E; Pasquet A; Raffi F; Pintado C; Chidiac C; Chas J; Charbonneau P; Delaugerre C; Suzan-Monti M; Loze B; Fonsart J; Peytavin G; Cheret A; Timsit J; Girard G; Lorente N; Préau M; Rooney JF; Wainberg MA; Thompson D; Rozenbaum W; Doré V; Marchand L; Simon MC; Etien N; Aboulker JP; Meyer L; Delfraissy JF;
N Engl J Med; 2015 Dec; 373(23):2237-46. PubMed ID: 26624850
[TBL] [Abstract][Full Text] [Related]
35. First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine.
Siguier M; Mera R; Pialoux G; Ohayon M; Cotte L; Valin N; Ghosn J; Cua E; Pintado C; Chas J; Barriere G; Durand F; Molina JM
J Antimicrob Chemother; 2019 Sep; 74(9):2752-2758. PubMed ID: 31219561
[TBL] [Abstract][Full Text] [Related]
36. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
[TBL] [Abstract][Full Text] [Related]
37. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa.
Jamieson L; Gomez GB; Rebe K; Brown B; Subedar H; Jenkins S; Shoko N; Bekker LG; Johnson LF; Meyer-Rath G
AIDS; 2020 May; 34(6):883-891. PubMed ID: 32004205
[TBL] [Abstract][Full Text] [Related]
38. Study on Pre-Exposure Prophylaxis Regimens among Men Who Have Sex with Men: A Prospective Cohort Study.
Wu D; Tao H; Dai J; Liang H; Huang A; Zhong X
Int J Environ Res Public Health; 2019 Dec; 16(24):. PubMed ID: 31818006
[No Abstract] [Full Text] [Related]
39. Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen.
Mujugira A; Baeten JM; Hodges-Mameletzis I; Haberer JE
Drugs; 2020 Dec; 80(18):1881-1888. PubMed ID: 33040323
[TBL] [Abstract][Full Text] [Related]
40. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
